References
- Abrahamsen J, Bakken A, Bruserud O. Cryopreserving human peripheral blood progenitor cells with 5-percent rather than 10-percent DMSO results in less apoptosis and necrosis in CD 34+ cells. Transfusion. 2002;42: 1573–80.
- Fois E, Desmartin M, Benhamida S, Xavier F, Vanneaux V, Rea D, . Recovery, viability and clinical toxicity of thawed and washed haematopoetic progenitor cells: analysis of 952 autologous peripheral blood stem cell transplantations. Bone Marrow Transplant. 2007;40:831–35.
- Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996;5:213–26.
- Sartor M, Antonenas V, Garvin F, Webb M, Bradstock KF. Recovery of viable CD 34+ cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transplant. 2005;36:199–204.
- Galmes A, Besalduch J, Bargay J, Novo A, Morey M, Jose M . Long term storage at −80°C of hematopoietic progenitor cells with 5-percent dimethysulfoxide as the sole cryoprotectant. Transfusion. 1999;39:70–3.
- Davis JM, Rowley SD, Braine HG, Piantadosi S, Santos GW . Clinical toxicity of cryopreserved bone marrow graft infusion. Blood. 1990; 75: 78-1-86.
- Stroncek DF, Fautsch SK, Lasky LC, Hurd DD, Ramsay Nk, McCullough J . Adverse reactions in patients transfused with cryopreserved marrow. Transfusion. 1991;31:521–26.